ABSTRACT Background: SLC22A23 is an orphan gene in the SLC22 family of organic membrane transporters, and its single-nucleotide polymorphism rs17309827-T was recently nominally associated with intestinal inflammation in a genome-wide association study. Other polymorphisms in the SLC22A23 gene have been associated with diseases with an inflammatory component, and polymorphisms in related genes in the SLC22 family have been repeatedly associated with inflammatory bowel disease (IBD). Objective: In a candidate-gene study using a well-phenotyped, highly monitored, Manitoban white cohort, we investigated whether variations in SLC22A23 were associated with intestinal inflammation. Design: Selected genetic variations were genotyped by using fluorescentbased assays or a polymerase chain reaction-restriction fragment length polymorphism analysis in 160 individuals with Crohn disease, 149 individuals with ulcerative colitis, and 142 healthy control subjects to determine genetic associations. Results: Homozygocity for single-nucleotide polymorphisms rs4959235-TT and rs950318-GG was associated with IBD, whereby 6% of patients (18 of 311 cases) carried these genotypes, but they were not seen in healthy controls. Conclusion: Associations reported in this article add to the emerging evidence that SLC22A23 variants could modify IBD risk. However, the biology of the gene and impact of variations on the gene's functions need to be tested to validate a causative role.
INTRODUCTION
Inflammatory bowel disease (IBD) 5 is characterized by chronic inflammation of the gastrointestinal tract with the principal forms Crohn disease (CD) and ulcerative colitis (UC). Mostly unknown environmental and genetic factors contribute to the immune dysregulation, which determine the development, maintenance, and severity of the disease (1, 2) .
Recent advances in genome-wide association studies (GWASs) have contributed to the understanding of genetic factors in intestinal inflammation. Although most genetic variations associated with IBD are in immunoregulatory pathways (3, 4) , polymorphisms in 2 genes that encode organic cation transporters SLC22A4 and SLC22A5 have been repeatedly associated with IBD (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Organic cation transporter proteins are involved in the absorption, distribution, and excretion of therapeutic drugs, xenobiotics, and food compounds (19) . Functional variations in organic cation transporter genes could affect the cellular uptake, pharmacokinetics, and, thus, the bioactivity of unknown organic ions, which might modulate the susceptibility and severity of IBD or other related common and complex diseases. Hence, we hypothesized that an organic ion imbalance as a consequence of polymorphisms in transporter genes contributes to the cause of IBD.
The single-nucleotide polymorphism (SNP) rs17309827-T, which is located in a gene in the SLC22 transporter family SLC22A23, has been associated with IBD in a GWAS (3, 20) , which has strengthened the hypothesis that imbalances of organic ions might modulate IBD risk. In addition to IBD, polymorphisms in the SLC22A23 gene have been associated with other complex diseases that have an inflammatory component, such as endometriosis-related infertility (21) , and the clearance of antipsychotic drugs (22) . SLC22A23 SNP rs17136561 was nominally associated with the development of asthma in individuals with impaired allergic status, although the results did not reach an overall genome-wide significance (OR: 1.64; 95% CI: 1.33, 2.02; P = 2.3 3 10
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) (23). SLC22A23 was also 1 of 6 genes in which expressions could be used to predict the recurrence of triple-negative breast cancer in a cohort of Taiwanese women (24) .
On the basis of the emerging evidence associating genetic variations in SLC22A23 with IBD and other diseases having an inflammatory component, and because the gene is related to SLC22A4 and SLC22A5, which have repeatedly been associated with IBD, additional study of the gene and its polymorphisms is warranted. In this article, we report the results of a candidate-gene study that we conducted in a well-phenotyped, Manitoban white IBD cohort, which showed that polymorphisms of the SLC22A23 gene were associated with UC, CD, and IBD overall.
SUBJECTS AND METHODS

Study population
The study population included IBD patients from the Canadian Manitoba Inflammatory Bowel Disease Cohort initiated in 2002 and described previously (25) . A total of 311 age-and sex-matched white IBD patients (162 CD and 149 UC patients) and 142 healthy control subjects drawn from the general population who did not have personal or first-degree relatives with any chronic immune disease were included in the study. CD and UC status was determined on the basis of radiologic, endoscopic, and histologic data, and phenotypes were assigned according to the Montreal classification (26) and are shown in Table 1 .
Genotyping
Genomic DNA was isolated from blood as described previously (27) . Polymorphism rs17309827 was genotyped by using a polymerase chain reaction-restriction fragment length polymorphism analysis, and rs9503518, rs6923667, and rs4959235 were genotyped by using TaqMan SNP genotyping assays (Applied Biosystems).
To determine rs17309827 genotypes, 219 nucleotides were amplified between the sense primer GGAACGTACAATTCTGCA and antisense primer GCATGTGAGCGTTTGATG by using Taq Polymerase (New England BioLabs) according to the manufacturer's protocol and following cycling conditions: initial denaturation at 958C for 30 s followed by 35 cycles of denaturation at 958C for 15 s, annealing at 508C for 15 s, extension at 688C for 2 min, and final extension at 688C for 5 min. Amplicons were digested with the restriction endonuclease NlaIII (New England BioLabs) by using the manufacturer's recommendations, whereby the enzyme cuts the G variant in fragments of 171 and 48 nucleotides, whereas the T variant does not possess an NlaIII restriction site. Restriction patterns of individual samples were determined after gel electrophoresis with a 2% UltraPure agarose gel (Invitrogen) via ethidium bromide staining under UV light and imaged in a UV imaging system (Gel Doc; BIO-RAD). The efficiency of the amplification and restriction digest was determined by incorporating positive and negative controls amplified from previously the subcloned amplicon of known genotype in each set of restriction fragment length polymorphism analysis. In addition, rs9503518, rs6923667, and rs4959235 were genotyped with TaqMan SNP genotyping assays (catalog nos. 4351379, 4351379, 4351379, respectively; Applied Biosystems) by using the TaqMan GTXpress Master Mix (Applied Biosystems) and assays recommended by the manufacturer.
Statistical analyses
Polymorphisms were tested for Hardy-Weinberg equilibrium. The case-control association of genotypes for each SNP with CD, UC, and overall IBD risks was tested by using logistic regression. ORs and 95% CIs of ORs were determined for 2 of 3 genotypes (the carrier of the minor alleles) relative to the third genotype (homozygote for the major allele) as a reference genotype. The analysis was carried out with SAS 9.2 software (SAS Institute). Linkage disequilibrium and haplotype blocks were performed with Haploview 4.2 software (Broad Institute) (28) by using the default method (29) . 
Predicted functional impact of SNPs and population distributions
The predicted functional impact of individual SNPs was assessed via the SNP Function Prediction tool FuncPred (30) , which includes the assessment of functional implications of nonsynonymous SNPs, splicing regulation, stop codon changes, polymorphism phenotyping (PolyPhen; Harvard), SNPs3D (OMICtools), transcription-factor binding sites, microRNA binding sites, regulatory potential, and conservation. HapMap (31) data were assessed via the Ensembl Genome browser (32) and processed with the Microsoft Excel 2013 program (Microsoft Corp). All database analyses were conducted between 10 and 22 July 2013.
RESULTS
Genotype distributions conformed to the Hardy-Weinberg equilibrium for all groups, and frequencies are listed in Tables 2  and 3 . All frequencies were in the range reported for white populations in HapMap (31) and SNP500 (33) databases.
Homozygote individuals for genotypes rs4959235-TT and rs9503518-GG were exclusively shown in UC and CD patients and significantly associated with the respective phenotypes ( Table 2) . Because of an overrepresentation in UC patients, the rs9503518-G allele was also associated with this phenotype (Table 2) .
Moreover, rs4959235-TT and rs9503518-GG homozygosity was associated with IBD overall because both genotypes were exclusive to patients and not healthy controls (Table 3 ). The OR for disease-associated genotypes as calculated by logistic regression were called infinite (N), which decisively established significance even though P values could not be called for the observed genotype distribution, because a comparison with a group equaling zero was not permissive. Therefore, we extrapolated significance through the following rationale: when the genotype distribution between IBD and control populations was considered, the overall probability of IBD was as follows:
Nine distinct-disease individuals but no healthy controls carried genotypes rs4959235-TT and rs9503518-GG, and the likelihood for such a distribution was as follows:
From this very low likelihood we made the conjecture that homozygotes for both SNPs had a significantly higher rate of affliction. In addition, rs6923667-CT heterozygosity was significantly associated with CD but not UC compared with the controls (Table 2) . None of the SNPs were associated with any phenotypic subtype of CD or UC. 1 Associations were determined by using logistic regression, and significant associations were determined as follows: ORs calculated by using logistic regression were called infinite (N) for disease-associated genotypes, which decisively established significance even though P values could not be called for the observed genotype distribution because a comparison with a group equaling zero was not permissive. Significance was established through the following rationale: when the genotype distribution between IBD and control populations was considered, the overall probability of IBD was 311 O (311 + 142) = 0.69. Nine distinct-disease individuals but no healthy controls carried genotypes rs4959235-TT and rs9503518-GG, and the likelihood for such a distribution was 0.69 29 = 0.0354. From this very low likelihood, we made the conjecture that the homozygotes for both SNPs have a significantly higher rate of affliction. The 9 cases of rs4959235-TT and rs9503518-GG homozygosity were in distinct individuals. IBD, inflammatory bowel disease; SNP, single-nucleotide polymorphism. 2 Significant association.
DISCUSSION
Genotypes rs4959235-TT and rs950318-GG in the SLC22A23 gene were associated with UC, CD, and IBD overall in our Manitoban white cohort. Both genotypes were exclusively present in IBD patients but not healthy controls. Previously, another SLC22A23 allele rs17309827-T was nominally associated with IBD in a GWAS meta-analysis (3) and independently of risk of stricturing phenotypes in CD (34) . Thus, our data add to the emerging evidence for associations of SLC22A23 genotypes with IBD.
Although the results of our study are in agreement with results of the aforementioned GWAS meta-analysis (3), they contrast with results from reports in a Swedish white cohort (35) (36) (37) and British UC cohort (38) . The discrepancy between results may be explained by differences in the nature of the cohorts as well as interstudy discrepancies that produced different confounders, such as the selection of tag SNPs, different ethnic backgrounds, phenotyping methodologies, or underpowered data sets. Although our cohort was moderately sized, the validity of our results was supported by the closely monitored, well-phenotyped nature of the cohort and further shown by the high number of studies this cohort has produced that have replicated GWAS findings of IBD associations (39) .
Significantly, our studies were distinguished from others studies that investigated associations with IBD by our decisive results that homozygotes for the novel SNPs rs4959235-TT and rs950318-GG were exclusively present in the Manitoban white IBD patients but not at all in healthy controls (Tables 2 and 3 ). In addition, our studies indicated that both SNPs affect IBD risk independently because they are in distinct linkage blocks ( Figure  1 ) and show distinct pattern of inheritance. Homozygotes for SNP rs4959235-TT have elevated disease risk (Table 2) , which is indicative of recessive inheritance. In contrast, both rs9503518-GG homozygosity as well as the presence of the G allele elevated disease risk relative to the allelic presence ( Table 2) .
Because of the indication of recessive inheritance, we further investigated if SNP rs4959235-TT homozygosity could play a role in disease risk across ethnicities by using existing HapMap data. The IBD risk allele rs4959235-T was not shown in Asian and sub-Saharan populations, in whom IBD incidence rates are lowest (Table 4) (40). The rs4959235-T allele reaches allelic frequencies #19% in European cohorts (Table 4) (Table 4 ). The findings in the European HapMap cohorts are in concordance with data in our cohort of Manitoban whites, whereby we did not observe rs4959235-TT homozygotes in healthy individuals. In contrast, rs4959235-TT homozygotes have been reported in cohorts of American ancestry, in whom C/T heterozygosity is similar to that of Europeans (Table 4 ). The presence of healthy TT homozygotes in American ancestry might indicate a less-severe disease phenotype because of the distinct genetic background, which could explain the retention of both alleles throughout human evolution.
Although current prediction tools do not indicate a functional impact for either SNP rs4959235 (which is noncoding in intron 4) or SNP rs9503518 (which is synonymous in exon 10) (30), additional study is warranted to determine whether these SNPs tag causative variations. Next-generation sequencing data have confirmed this possibility because 8 rare nonsynonymous variations and one frame-shift mutation predicted to be detrimental have been identified within the linkage region of these SNPs (Table 5 ) (42) . The presence of rare nonsynonymous SNPs should be considered in future genetic and functional investigations.
SLC22A23 is an orphan gene in the SLC22 family of organic cation and anion transporters. Its genomic organization and variations have not been comprehensively described, and its substrate is unknown (43) . However, our results implied that SLC22A23's unknown substrate could be an intracellular antioxidant. As noted, variations in the 2 related genes SLC22A4 and SLC22A5, which encode for membrane transporters of ergothioneine (44) (45) (46) and carnitine (47) (48) (49) (50) , respectively, have consistently been associated with IBD (5, 7, 10, (14) (15) (16) 18) . Because both carnitine and ergothioneine are intracellular antioxidants (51-53), we hypothesize that altered transport kinetics could lead to a disturbed intracellular redox state and, thus, elevated IBD susceptibility. Our, to our knowledge, novel hypothesis that intracellular redox status could be compromised through the altered membrane transport of antioxidants has been further supported by the recent association of SNPs in the ascorbic acid transporter SLC23A1 with CD (54).
In conclusion, we present evidence that genetic variations in the SLC22A23 locus contribute to the susceptibility to IBD in a small fraction of white patients. With consideration of the existing association and biological studies, we theorize that genetic variations in membrane transporters contribute to a disturbed intracellular redox status through an altered antioxidant uptake. If future biological studies validate the proposed mechanism or mechanisms of redox disturbance, a specific dietary intervention can be developed for individuals who carry risk genotypes. A genotype-specific nutritional intervention could offer a cost-effective alternative to existing immunomodulation therapy with significantly reduced adverse effects. However, we caution that current knowledge suggests that applicability might be very specific and likely limited. Of 163 independent IBD risk loci identified to date (55) , effect sizes of individual SNPs explain, at best, 14% of the disease phenotype (56) . At present, SLC22A23 variations or variations in other membrane transporters account for a significantly less effect size. Nevertheless, future investigations could reveal transporter variations that have a greater impact. Because individuals with risk genotypes can be identified cost effectively, and IBD incidences are rising worldwide, growing numbers of individuals could benefit from novel nutritional interventions in the future.
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